3-(四氢-2H-吡喃-2-基氧基)丙烷-1-醇 | 2162-33-6

• 物质功能分类: 医药中间体 - 吡喃类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 3-(四氢-2H-吡喃-2-基氧基)丙烷-1-醇
• 英文名称: 3-(tetrahydropyran-2-yloxy)propan-1-ol
• 英文别名: 3-((tetrahydro-2H-pyran-2-yl)oxy)propan-1-ol；3-Tetrahydropyranyloxy-1-propanol；3-(oxan-2-yloxy)propan-1-ol
• CAS: 2162-33-6
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: JZQJFSZRLAICJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  3-(四氢-2H-吡喃-2-基氧基)丙烷-1-醇 在 咪唑 、 碘 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以91%的产率得到1-iodo-3-(tetrahydropyran-2-yloxy)propane
  参考文献：
  名称：

  Synthesis of cycloalkanone-fused cyclopropanes by Au(I)-catalyzed oxidative ene-yne cyclizations

  摘要：

  Au(I)-catalyzed oxidative cyclizations that successfully convert 1,5-ene-ynes and a 1,6-ene-yne to the corresponding cycloalkanone-fused cyclopropanes are described. This Au(I)-catalyzed oxidative cyclization can be effectively applied to various substrates and is an alternative to the previously used intramolecular cyclopropanation that required potentially explosive diazo compound. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.10.084
• 作为产物：
  描述：

  2-(3-Phenylmethoxypropoxy)oxane 在 5% Pd on active carbon Ti-HMS 、 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以83%的产率得到3-(四氢-2H-吡喃-2-基氧基)丙烷-1-醇
  参考文献：
  名称：

  Selective acceleration for deprotection of benzyl ethers with Ti-HMS

  摘要：

  Ti-HMS, a TI-loaded hexagonal mesoporous silica, was found to accelerate deprotection of benzyl ethers under hydrogenolytic conditions with palladium catalyst. Such acid-sensitive functional groups as silyl ether and acetal moieties in the molecule were little affected by Ti-HMS, which possesses Lewis acid sites due to Ti-atom. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02145-5

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists
  作者：Hiroyuki Kai、Tohru Horiguchi、Takayuki Kameyma、Naohiro Onodera、Naohiro Itoh、Yasuhiko Fujii、Yusuke Ichihashi、Keiichiro Hirai、Takuya Shintani、Kenichiroh Nakamura、Kazuhisa Minami、Erika Kasai、Sosuke Yoneda、Yuki Murakami、Hiroko Ogawa、Ryouko Sekimoto、Shunji Shinohara、Osamu Yoshida、Noriyuki Kurose

  DOI：10.1016/j.bmcl.2021.128384

  日期：2021.11

  work, we discovered a lead compound and conducted initial SAR studies on a novel series of dioxotriazines to identify the compound as one of the P2X3 receptor antagonists. This compound showed high P2X3 receptor selectivity and a strong analgesic effect. Although not selected for clinical development, the compound was evaluated from various aspects as a tool compound. In the course of the following study

  在之前的工作中，我们发现了一种先导化合物，并对一系列新型二氧杂三嗪进行了初步 SAR 研究，以确定该化合物是 P2X3 受体拮抗剂之一。该化合物显示出高 P2X3 受体选择性和强镇痛作用。虽然没有选择用于临床开发，但该化合物作为工具化合物从各个方面进行了评估。在以下研究过程中，基于药代动力学/药效学 (PK/PD) 分析修改了二氧杂三嗪的分子结构。作为这些 SAR 研究的结果，Sivopixant (S-600918) 被确定为具有强效和选择性拮抗活性的临床候选药物 (P2X3 IC 50 , 4.2 nM; P2X2/3 IC 50, 1100 nM) 和对异常性疼痛的大鼠部分坐骨神经结扎模型 (Seltzer model) 有很强的镇痛作用 (ED 50 , 0.4 mg/kg)。
• [EN] TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ALCÉNIQUES TÉTRASUBSTITUÉS ET LEUR UTILISATION
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2016196342A1

  公开（公告）日：2016-12-08

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

  本文披露了化合物或其药用可接受盐，并使用这些化合物治疗乳腺癌的方法，通过向需要治疗的受试者施用这些化合物或其药用可接受盐的治疗有效量。乳腺癌可能是ER阳性乳腺癌，需要治疗的受试者可能表达突变的ER-α蛋白。
• Polystyrene-supported GaCl3: A new, highly efficient and recyclable heterogeneous Lewis acid catalyst for tetrahydropyranylation of alcohols and phenols
  作者：Ali Rahmatpour

  DOI：10.1016/j.poly.2012.06.063

  日期：2012.8

  highly chemoselective method for tetrahydropyranylation of alcohols and phenols with 3,4-dihydro-2H-pyran (DHP) in the presence of polystyrene-supported gallium trichloride (PS/GaCl3) as a highly active and reusable heterogeneous Lewis acid catalyst at room temperature is presented. In this catalytic system, primary, secondary and tertiary alcohols, as well as phenols, were converted to the corresponding

  在聚苯乙烯负载的三氯化镓（PS / GaCl 3）存在下，用3,4-二氢-2 H-吡喃（DHP）对醇和酚进行四氢吡喃基化的一种新的，简单且高度化学选择性的方法）是在室温下具有高活性和可重复使用的非均相路易斯酸催化剂。在该催化体系中，伯，仲和叔醇以及苯酚以短的反应时间和高收率转化为相应的四氢吡喃基（THP）醚。异质催化剂在吡喃基化反应中具有高可重复使用性和稳定性，并且被回收了数次，其活性损失可忽略不计且催化剂浸出可忽略不计，并且也不需要再生。该方法对对称二醇的单四氢吡喃基化反应也显示出良好的化学选择性。